Howe & Rusling’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-40
| Closed | -$7K | – | 1060 |
|
|
2021
Q2 | $7K | Hold |
40
| – | – | ﹤0.01% | 554 |
|
|
2021
Q1 | $6K | Buy |
40
+9
| +29% | +$1.39K | ﹤0.01% | 597 |
|
|
2020
Q4 | $5K | Sell |
31
-4
| -11% | -$514 | ﹤0.01% | 643 |
|
|
2020
Q3 | $4K | Hold |
35
| – | – | ﹤0.01% | 624 |
|
|
2020
Q2 | $4K | Hold |
35
| – | – | ﹤0.01% | 589 |
|
|
2020
Q1 | $3K | Hold |
35
| – | – | ﹤0.01% | 606 |
|
|
2019
Q4 | $4K | Hold |
35
| – | – | ﹤0.01% | 603 |
|
|
2019
Q3 | $3K | Hold |
35
| – | – | ﹤0.01% | 658 |
|
|
2019
Q2 | $5K | Sell |
35
-9
| -20% | -$1.16K | ﹤0.01% | 551 |
|
|
2019
Q1 | $6K | Buy |
44
+2
| +5% | +$249 | ﹤0.01% | 525 |
|
|
2018
Q4 | $4K | Sell |
42
-12
| -22% | -$1.42K | ﹤0.01% | 594 |
|
|
2018
Q3 | $8K | Hold |
54
| – | – | ﹤0.01% | 554 |
|
|
2018
Q2 | $7K | Hold |
54
| – | – | ﹤0.01% | 515 |
|
|
2018
Q1 | $6K | Sell |
54
-10
| -16% | -$1.2K | ﹤0.01% | 592 |
|
|
2017
Q4 | $8K | Buy |
64
+9
| +16% | +$1.1K | ﹤0.01% | 502 |
|
|
2017
Q3 | $8K | Hold |
55
| – | – | ﹤0.01% | 525 |
|
|
2017
Q2 | $7K | Hold |
55
| – | – | ﹤0.01% | 567 |
|
|
2017
Q1 | $7K | Buy |
55
+13
| +31% | +$1.68K | ﹤0.01% | 607 |
|
|
2016
Q4 | $5K | Buy |
+42
| New | +$5.14K | ﹤0.01% | 698 |
|
|
2016
Q2 | – | Sell |
-5
| Closed | -$1K | – | 1083 |
|
|
2016
Q1 | $1K | Hold |
5
| – | – | ﹤0.01% | 972 |
|
|
2015
Q4 | $1K | Hold |
5
| – | – | ﹤0.01% | 956 |
|
|
2015
Q3 | $1K | Hold |
5
| – | – | ﹤0.01% | 978 |
|
|
2015
Q2 | $1K | Buy |
+5
| New | +$863 | ﹤0.01% | 1001 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM